ロード中...
Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
Treating patients suffering from EGFR mutant non-small cell lung cancer (NSCLC) with first-generation EGFR tyrosine kinase inhibitors (EGFR TKI) provides excellent response rates. However, approximately 60% of all patients ultimately develop drug resistance due to a second T790M EGFR TKI mutation. I...
保存先:
| 出版年: | Molecules |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6274483/ https://ncbi.nlm.nih.gov/pubmed/27827863 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/molecules21111462 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|